Anti-cancer drugs and their effect on the ubiquitin cycle

Anti-cancer drugs and their effect on the ubiquitin cycle - Anti-cancer drugs and their effect on the ubiquitin cycle

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31019

Enrollment

110

Registered

2007-11-20

Start date

2007-09-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer hematologic malignancies

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. hematologic malignancy 2. treatment with anthracyclins and/or proteasome inhibitors

Exclusion criteria

Exclusion criteria: prior treatment with either anthracyclins or proteasome inhibition

Design outcomes

Primary

Measure	Time frame
To decipher the effect of anthracyclins on the ubiquitin cycle in living cells and to decipher the biological reason for the effect on uH2 by both anthracyclins and proteasome inhibitors, and both drugs in combination.	—

Secondary

Measure	Time frame
For the clinical part of the research project the effect of anthracyclines and/or proteasome inhibitors on histone de-ubiquitination as observed in vivo after administration of these drugs, will be correlated with outcome of the patients (response to treatment and progression-free survival).	—

Countries

Netherlands

Outcome results